Please login to the form below

Not currently logged in
Email:
Password:

haemophilia B

This page shows the latest haemophilia B news and features for those working in and with pharma, biotech and healthcare.

Pfizer doses first patient in investigational haemophilia drug trial

Pfizer doses first patient in investigational haemophilia drug trial

Company is evaluating marstacimab in severe haemophilia A/B patients. Pfizer has dosed the first patient in its phase 3 study of marstacimab, an investigational drug being evaluated for the treatment ... haemophilia B.

Latest news

More from news
Approximately 5 fully matching, plus 53 partially matching documents found.

Latest Intelligence

  • 20 for 2020 – Five pharma leaders to watch in 2020 20 for 2020 – Five pharma leaders to watch in 2020

    pipeline. The company submitted its lumasiran candidate for primary hyperoxaluria to the FDA and has another ATTR amyloidosis candidate – called vutrisiran – in late-stage along with Sanofi-partnered fitusiran for haemophilia

  • Deal Watch January 2018

    s closing price on 19 January), Sanofi gains the marketed products, Eloctate (haemophilia A therapy) and Alprolix (haemophilia B therapy), as well as a pipeline of candidates focused on rare blood ... Portfolio/pipeline in haemophilia and other rare

  • Deal Watch August 2016 Deal Watch August 2016

    premiums. One commentator suggested BioMarin could be a Plan B for Sanofi. ... This will help with the collaboration with Spark Therapeutics that is developing a treatment for haemophilia B that incorporates a bio-engineered rAAV vector and the academic

  • A rare opportunity A rare opportunity

    Sobi, handing Sobi commercialisation control over the haemophilia A treatment just four months after it received EU approval. ... Last month Alprolix was approved by the European Commission, becoming the first licenced long-acting treatment for

  • Deal Watch February 2016 Deal Watch February 2016

    of haemophilia A and B.

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Origins Insights

Our goal is to identify and embed transformational patient insights as a fundamental part of the drug development process. As...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....